Emily M. Leproust, Ph.D., is the Chief Executive Officer and Chair of the Board at Twist Bioscience Corporation, a leading synthetic biology and genomics company. Dr. Leproust holds a Ph.D. in Organic Chemistry from the University of Houston and has had a distinguished career in the life sciences industry. Before founding Twist Bioscience, she served as Vice President of Research and Development at Agilent Technologies, where she played a pivotal role in developing innovative genomic solutions. Her expertise in DNA synthesis and sequencing technologies has been instrumental in positioning Twist Bioscience as a frontrunner in the field of synthetic biology. Under Dr. Leproust's leadership, Twist Bioscience has made significant strides in revolutionizing gene synthesis and next-generation sequencing. The company has developed a proprietary silicon-based DNA synthesis platform that enables rapid and cost-effective production of synthetic genes, which has broad applications in research, pharmaceuticals, and agriculture. Dr. Leproust's visionary approach has led to the expansion of Twist Bioscience's product offerings, including the introduction of data storage solutions that leverage the potential of DNA as a high-density storage medium. Her commitment to innovation and excellence has earned her recognition as a trailblazer in the industry, and she continues to drive Twist Bioscience towards new frontiers in synthetic biology. As CEO and Chair of the Board, Dr. Leproust oversees the strategic direction and operational execution of Twist Bioscience. Her leadership has been crucial in navigating the company through rapid growth and scaling its capabilities to meet the increasing demand for synthetic DNA. Dr. Leproust's dedication to fostering a culture of innovation and collaboration has attracted top talent to the company and strengthened its position as a leader in the synthetic biology market. Her contributions to the field extend beyond Twist Bioscience, as she actively participates in industry forums and initiatives aimed at advancing the potential of synthetic biology for societal benefit.